The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

Dec. 21, 2022
Applicant:

Amgen Research (Munich) Gmbh, Munich, DE;

Inventors:

Tobias Raum, Munich, DE;

Claudia Blümel, Munich, DE;

Christoph Dahlhoff, Munich, DE;

Patrick Hoffmann, Munich, DE;

Peter Kufer, Munich, DE;

Ralf Lutterbüse, Munich, DE;

Elisabeth Nahrwold, Munich, DE;

Jochen Pendzialek, Munich, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/07 (2010.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); C07K 14/475 (2006.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/11 (2025.01); A61K 40/4225 (2025.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C12N 5/06 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05); A61K 2239/57 (2023.05); C07K 16/22 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.


Find Patent Forward Citations

Loading…